PMID- 32713191
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20210709
IS  - 1555-3892 (Electronic)
IS  - 0963-6897 (Print)
IS  - 0963-6897 (Linking)
VI  - 29
DP  - 2020 Jan-Dec
TI  - A Case of Successful Allogeneic Hematopoietic Stem Cell Transplantation for 
      HHV8-Positive Castleman's Disease with a Review of the Literature.
PG  - 963689720943571
LID - 10.1177/0963689720943571 [doi]
LID - 0963689720943571
AB  - OBJECTIVE: To investigate the long-term clinical efficacy of allogeneic 
      hematopoietic stem cell transplantation (allo-HSCT) for patients with human 
      herpes virus 8 (HHV8)-positive multicentric Castleman's disease (MCD). METHODS: A 
      17-year-old female patient was admitted to Henan Provincial People's Hospital 
      with the complaint of febrile for half a month, headache, and enlarged 
      superficial lymph nodes on October 5, 2010. HHV8-positive mixed cellular 
      Castleman's disease was found by pathological diagnosis of lymph nodes biopsy. 
      After the administration of CHOP and Hyper-CVAD-B, the patient was still febrile, 
      we administrated the followed COAP, two courses of VAD(Vincristine, Adriamycin, 
      Dexamethasone), the patient received CR. Six months after CR, the patient 
      relapsed, we administrated VAD and two courses of bortezomide+dexamethasone 
      chemotherapy, and then the patient received PR. After that, the patient underwent 
      allo-HSCT from his human leukocyte antigen (HLA)-matched unrelated donor after 
      conditioning with Bu/Cy+Etoposide+Smoustin.graft-vs-host disease (GVHD) 
      prophylaxis, which consisted of ATG (7.5 mg/kg, qd, ivdrip) from d-5 to d-2, 
      cyclosporine (3 mg/kg/d, qd, ivdrip, for 24 h) started from day-1, MMF(0.5 g, 
      tid, po.) started from day+1 to +28, and MTX (15 mg per time, ivdrip, 
      d+1,+4,+7,+11). She received 3.5x10(6)/L CD34(+)cells and 8.1x10(8)/LMNC. 
      RESULTS: Granulocyte engraftment occurred on day+12, platelet engrafted on 
      day+14. Bone marrow biopsy showed normalization of trilineage hematopoiesis on 
      day+33, chimerism: 97.6%. The transplantation was successful and followed up for 
      7 years with CR. CONCLUSION: Allo-HSCT might cure patients with 
      refractory/relapsed HHV8+ MCD.
FAU - Wang, Zhen
AU  - Wang Z
AUID- ORCID: 0000-0002-5963-242X
AD  - Department of Hematology, Henan University People's Hospital, School of Clinical 
      Medicine, Henan University, Zhengzhou, Henan, PR China.
AD  - Department of Hematology, Henan Provincial People's Hospital and Zhengzhou 
      University People's Hospital Zhengzhou, PR China.
AD  - Both the authors contributed equally to this article.
FAU - Yang, Shiwei
AU  - Yang S
AD  - Institute of Hematology Henan Provincial People's Hospital, Zhengzhou, Henan, PR 
      China.
AD  - Henan Key Laboratory of Stem Cell Differentiation and Modification, Henan 
      Provincial People's Hospital, Zhengzhou, Henan, PR China.
AD  - Both the authors contributed equally to this article.
FAU - Zhu, Zunmin
AU  - Zhu Z
AD  - Department of Hematology, Henan Provincial People's Hospital and Zhengzhou 
      University People's Hospital Zhengzhou, PR China.
AD  - Institute of Hematology Henan Provincial People's Hospital, Zhengzhou, Henan, PR 
      China.
AD  - Henan Key Laboratory of Stem Cell Differentiation and Modification, Henan 
      Provincial People's Hospital, Zhengzhou, Henan, PR China.
FAU - Lei, Pingchong
AU  - Lei P
AD  - Department of Hematology, Henan Provincial People's Hospital and Zhengzhou 
      University People's Hospital Zhengzhou, PR China.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Hematology, Henan Provincial People's Hospital and Zhengzhou 
      University People's Hospital Zhengzhou, PR China.
FAU - Zhang, Ping
AU  - Zhang P
AD  - Department of Hematology, Henan Provincial People's Hospital and Zhengzhou 
      University People's Hospital Zhengzhou, PR China.
FAU - Sun, Kai
AU  - Sun K
AD  - Department of Hematology, Henan Provincial People's Hospital and Zhengzhou 
      University People's Hospital Zhengzhou, PR China.
LA  - eng
PT  - Case Reports
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
SB  - IM
MH  - Adolescent
MH  - Castleman Disease/pathology/*therapy/*virology
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Herpesvirus 8, Human/*isolation & purification
MH  - Humans
MH  - Sarcoma, Kaposi/pathology/*therapy/virology
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Homologous/methods
PMC - PMC7563820
OTO - NOTNLM
OT  - Castleman's disease
OT  - allogeneic
OT  - hematopoietic stem cell
OT  - multicentric type
OT  - transplantation
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/07/28 06:00
MHDA- 2021/07/10 06:00
PMCR- 2020/07/27
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2020/07/27 00:00 [pmc-release]
AID - 10.1177_0963689720943571 [pii]
AID - 10.1177/0963689720943571 [doi]
PST - ppublish
SO  - Cell Transplant. 2020 Jan-Dec;29:963689720943571. doi: 10.1177/0963689720943571.